Synthroid Hair and Skin Changes: What Levothyroxine Actually Does

How Thyroid Hormone Controls Hair Follicle Biology

Thyroid hormones regulate the hair follicle cycle at the cellular level. Both T3 and T4 act on thyroid hormone receptors expressed directly in the dermal papilla and outer root sheath of hair follicles, prolonging anagen (growth phase) and delaying premature entry into catagen (regression phase) 1.

Anagen Prolongation and Receptor Distribution

T3 binds thyroid hormone receptor beta-2 (THR-beta2) in the hair follicle with higher affinity than T4. A 2008 study by van Beek et al. Confirmed that human hair follicles express TRalpha1 and TRbeta1, and that T3 at physiologic concentrations (1 to 10 nM) significantly prolonged anagen duration in ex vivo follicle models 1. Levothyroxine supplies T4, which peripheral tissues, including skin fibroblasts and keratinocytes, convert to active T3 via type 2 deiodinase (DIO2).

The Telogen Effluvium Mechanism

When circulating T4 falls, from autoimmune destruction in Hashimoto thyroiditis, post-thyroidectomy, or iodine deficiency, follicles prematurely shift into telogen (resting phase). The clinical result is diffuse shedding two to four months later, because telogen normally lasts approximately 100 days before the hair strand releases 2. This lag explains why patients often seek care for hair loss months after a TSH has already risen. A 2018 review in the Journal of Clinical and Aesthetic Dermatology confirmed telogen effluvium as the predominant pattern in both hypo- and hyperthyroid states, with diffuse thinning at the crown and temples rather than the patterned recession seen in androgenetic alopecia 3.

What Happens to Hair on Levothyroxine

Three distinct patterns occur after starting levothyroxine:

1. Transient worsening (weeks 4 to 12). As TSH normalizes, dormant telogen hairs release simultaneously. Shedding can temporarily increase before new anagen hairs emerge. This is physiologic, not drug toxicity.
2. Gradual regrowth (months 3 to 6). Follicles re-enter anagen. Hair shaft diameter and tensile strength recover as keratinocyte proliferation resumes 4.
3. Persistent shedding (beyond 6 months). If hair loss continues after TSH is confirmed within range, concurrent causes, iron deficiency, androgenetic alopecia, alopecia areata, or over-replacement, require investigation 5.

How Hypothyroidism Damages Skin Before Treatment Starts

Skin is one of the most metabolically active tissues in the body, renewing its entire epidermis approximately every 28 days. Thyroid hormone deficiency slows this turnover sharply 6.

Dryness, Scaling, and Reduced Sebum

Low T4 reduces sebaceous gland activity and epidermal proliferation. The result is xerosis, dry, rough, flaky skin, that patients often attribute to aging or climate before a thyroid diagnosis is made. A 2013 study in Clinical Endocrinology found that skin hydration scores (measured by corneometry) were significantly lower in overt hypothyroid patients (mean TSH 42.3 mIU/L) compared to euthyroid controls, and improved by 34% after 12 weeks of levothyroxine titrated to TSH <2.5 mIU/L 6.

Myxedema: The Severe End of the Spectrum

Myxedema, the accumulation of glycosaminoglycans (primarily hyaluronic acid and chondroitin sulfate) in the dermis, produces the characteristic non-pitting, doughy swelling of severe hypothyroidism 7. Facial puffiness, periorbital edema, macroglossia, and a coarsened facial appearance all reflect this extracellular matrix expansion. With adequate levothyroxine replacement, hyaluronic acid synthesis normalizes and the swelling resolves over four to eight weeks, though complete resolution of severe myxedema may take six months 8.

Skin Pigmentation and Carotenemia

Subclinical and overt hypothyroidism can produce a yellow-orange tint to the skin, particularly the palms and soles, from carotenemia. Thyroid hormone is required for hepatic conversion of beta-carotene to retinol (vitamin A). With reduced conversion, carotene accumulates in the stratum corneum. This resolves without specific treatment once levothyroxine restores normal hepatic enzyme activity 9.

Levothyroxine Dosing and Its Direct Impact on Hair and Skin Outcomes

Getting the dose right is not an aesthetic preference. Under-replacement and over-replacement each produce distinct dermatologic findings, and both can perpetuate hair loss 5.

Under-Replacement: Persistent Hypothyroid Skin Signs

The 2014 ATA Guidelines on Hypothyroidism in Adults (Jonklaas et al.) state: "The goal of levothyroxine therapy is to restore TSH and free thyroxine levels to within normal reference ranges and to resolve the symptoms and signs of hypothyroidism" 5. When TSH remains above 4.0 mIU/L on therapy, skin dryness, brittle hair, and diffuse shedding typically persist because follicular T3 signaling is still suppressed 5.

Standard full-replacement dosing is approximately 1.6 mcg/kg/day of levothyroxine in healthy adults under 65. Older adults, those with cardiac disease, or those with long-standing hypothyroidism start at 25 to 50 mcg/day with titration every six to eight weeks 5. Reaching target TSH in a timely, consistent way is the single most effective intervention for thyroid-related hair loss.

Over-Replacement: Thyrotoxic Hair Thinning

Excess levothyroxine suppresses TSH below 0.1 mIU/L in non-cancer patients and accelerates the hair cycle. Follicles cycle through anagen faster, producing shorter, finer hairs and a net increase in daily shed counts 10. A 2014 review in the Journal of Thyroid Research noted that TSH suppression to <0.1 mIU/L for thyroid cancer management carries a documented risk of hair thinning and osteoporosis, requiring a risk-benefit reassessment at each visit 10.

Skin in over-replacement states becomes warm, sweaty, and thin, the opposite of hypothyroid xerosis. Patients sometimes misread improved energy and warmth as a sign the dose should be increased, while their hair is already signaling excess.

Formulation Differences and Absorption

Generic levothyroxine bioavailability ranges from 65% to 84% across manufacturers 11. Tirosint (levothyroxine soft gel capsule) eliminates dye fillers and lactose, which matter for patients with absorption disorders affecting T4 uptake. Switching formulations without a TSH recheck at six to eight weeks risks brief under- or over-replacement, and with it, a new round of telogen effluvium 12.

Diagnosing Thyroid-Related Hair Loss: The Clinical Workup

Hair loss is multi-factorial, and thyroid disease accounts for a fraction of all presentations. A structured workup prevents over-attribution and missed concurrent diagnoses 13.

Initial Laboratory Panel

The minimum panel for a patient on levothyroxine who presents with hair loss should include:

• TSH (with reflex free T4 if TSH is abnormal)
• Serum ferritin (target >70 mcg/L for hair regrowth, per most dermatology consensus)
• Complete blood count
• 25-hydroxyvitamin D
• Serum zinc
• Total testosterone and DHEA-S in women with concurrent scalp pattern thinning

Iron deficiency is the most common concurrent driver of telogen effluvium in premenopausal women on levothyroxine, because both autoimmune thyroid disease (Hashimoto) and iron-deficiency anemia share the same demographic peak 14.

Trichoscopy Findings

Dermoscopy of the scalp in telogen effluvium shows an increased proportion of vellus hairs and upright regrowing hairs (exclamation-point hairs absent, distinguishing this from alopecia areata). A trichogram pull test showing greater than 25% telogen hairs supports the diagnosis. These features do not specify thyroid etiology but confirm the effluvium pattern that thyroid correction addresses 3.

Differentiating Transient vs. Persistent Shedding

Transient post-treatment shedding resolves within six months of TSH normalization. If shedding continues beyond that point with TSH confirmed in the 0.5 to 2.5 mIU/L range, the differential expands to:

• Androgenetic alopecia (requires separate treatment with minoxidil or finasteride in appropriate candidates)
• Alopecia areata (requires dermatology referral)
• Nutritional deficiency (correct the deficiency first before adding hair-specific supplements)
• Polycystic ovary syndrome with hyperandrogenism 15

Skin-Specific Effects of Levothyroxine Therapy Over Time

Skin improvements on levothyroxine follow a predictable sequence, though individual variation is wide 8.

Weeks 4 to 8: Early Hydration Changes

Sebaceous gland activity resumes first. Patients typically report less flakiness and a reduction in skin tightness within the first four to eight weeks, even before TSH fully normalizes. Epidermal turnover rate begins to recover, though the full 28-day cycle means visible texture improvement lags behind subjective sensation by two to four weeks 6.

Months 2 to 4: Myxedema Regression

Glycosaminoglycan clearance is slower than sebum recovery. The doughy, non-pitting facial and pretibial edema of myxedema begins to resolve by weeks six to eight but may require three to four months for significant visible change. The 2009 review by Safer et al. Noted that pretibial myxedema, when present, is particularly slow to clear and may persist even after TSH normalizes 8.

Months 4 to 6: Pigment Normalization

Carotenemia-related yellowing resolves as hepatic beta-carotene conversion recovers. Patients do not require dietary restriction of carotene-rich foods during this period; the enzyme activity correction is sufficient 9. Skin tone generally returns to baseline by month five to six in patients who achieve stable euthyroid TSH.

Long-Term: Wound Healing and Collagen Synthesis

Thyroid hormone stimulates fibroblast collagen synthesis and wound contraction. Chronic untreated hypothyroidism impairs wound healing measurably 16. Long-term adequate levothyroxine replacement maintains dermal collagen density, though this benefit is difficult to quantify clinically without biopsy.

Practical Monitoring Framework for Hair and Skin on Levothyroxine

The table below outlines a structured approach, derived from ATA 2014 Guidelines and dermatologic consensus, for managing hair and skin concerns at each stage of levothyroxine therapy.

| Timepoint | TSH Check | Hair Assessment | Skin Assessment | Action If Abnormal | |---|---|---|---|---| | Baseline | Yes | Document shed rate; pull test | Document xerosis, myxedema grade | Correct dose; address ferritin if <70 mcg/L | | 6 to 8 weeks post-start or dose change | Yes | Note transient shedding | Check for early hydration improvement | Adjust dose if TSH out of 0.5 to 4.0 range | | 3 months | Yes + free T4 | Reassess shed rate | Assess myxedema regression | Investigate concurrent causes if shedding persists | | 6 months | Yes | Confirm regrowth or refer to derm | Confirm skin normalization | Dermatology referral if no improvement | | Annual | Yes | Routine | Routine | Reassess dose with age/weight changes |

Dose adjustments should occur no faster than every six to eight weeks to allow the hypothalamic-pituitary-thyroid axis to fully equilibrate. The ATA 2014 Guidelines specify: "Serum TSH should be measured 4 to 8 weeks after any dose change" 5.

Drug Interactions and Supplements That Affect Hair and Skin Outcomes

Several common medications and supplements interfere with levothyroxine absorption or thyroid function tests in ways that indirectly affect hair and skin 17.

Absorption Reducers

• Calcium carbonate: Reduces T4 absorption by up to 41% when taken simultaneously. Space levothyroxine four hours apart from calcium supplements 17.
• Ferrous sulfate (iron): Binds levothyroxine in the gut; space by at least two hours 18.
• Proton pump inhibitors (PPIs): Omeprazole and similar agents reduce gastric acid, impairing T4 dissolution. Tirosint liquid capsule formulation largely bypasses this interaction 17.

Biotin's Interference with TSH Testing

High-dose biotin (5 mg/day or more, commonly taken for hair growth) produces falsely low TSH and falsely elevated free T4 on immunoassay platforms that use streptavidin-biotin chemistry 19. The FDA issued a safety communication on this in 2017. A patient whose TSH appears suppressed while taking high-dose biotin may have their levothyroxine dose incorrectly reduced, triggering genuine under-replacement and renewed hair loss. Patients should stop biotin for at least 48 to 72 hours before any thyroid function test 19.

Minoxidil as an Adjunct

When androgenetic alopecia coexists with thyroid-related effluvium, minoxidil 2% or 5% topical solution may be used concurrently once TSH is stable. Minoxidil extends anagen duration through potassium channel opening in the dermal papilla, a mechanism independent of thyroid hormone 20. A 2018 systematic review confirmed efficacy for female pattern hair loss at 2% and 5% concentrations, with no interaction with levothyroxine pharmacokinetics 20.

Special Populations: Pregnancy, Postpartum, and Aging Skin

Pregnancy

Levothyroxine requirements increase by 20% to 50% during pregnancy, typically within the first four to six weeks of gestation, because of rising TBG (thyroxine-binding globulin) driven by estrogen and increased T4 turnover 5. Under-replacement during pregnancy causes the same telogen effluvium seen in non-pregnant hypothyroid patients, but the postpartum hair shed is compounded by the physiologic postpartum effluvium that affects nearly 90% of women between months two and five after delivery 21. Distinguishing postpartum thyroiditis-driven effluvium from normal postpartum shedding requires TSH measurement.

Postpartum Thyroiditis

Postpartum thyroiditis affects 5% to 10% of women in the first year after delivery 22. The transient hypothyroid phase produces hair shedding that overlaps temporally with normal postpartum effluvium, making TSH measurement essential in this group. Women with pre-existing Hashimoto thyroiditis have a 25% risk of developing postpartum thyroiditis, per ATA data 22.

Aging Skin and Dose Recalibration

In adults over 65, levothyroxine requirements decrease because lean body mass declines and T4 clearance slows. Over-replacement is common in older adults whose doses were set in their 40s and never adjusted. TSH targets for adults over 70 are generally accepted as 1.0 to 4.0 mIU/L rather than the tighter 0.5 to 2.5 range used in younger adults 5. Overcorrection in this group accelerates skin thinning from atrophic dermal changes associated with iatrogenic thyrotoxicosis 10.